This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Aurinia Pharmaceuticals Inc.
Drug Names(s): TAFA93
Description: TAFA93 is a novel small molecule prodrug of the mTOR inhibitor rapamycin. mTOR (mammalian Target Of Rapamycin) is a cellular enzyme that plays a key role in cell growth and proliferation.
Deal Structure: On September 29, 2005, Isotechnika signed an exclusive worldwide licensing agreement with Atrium Medical Corporation for the use of TAFA93 and ISA247 specifically with drug eluting devices for the non-systemic treatment of vascular, cardiovascular disorders, target vessel and tissue disorders.
Atrium paid an upfront liscensing fee of $3,000,000. Atrium will pay milestone and royalty payments to Isotechnika upon approval of a medical device product which incorporates TAFA93, ISA247 or the combination of both drugs. Isotechnika is required to complete Phase Ib trial for TAFA93. Atrium will conduct and be financially responsible for all development costs of the medical device product program. Isotechnika will manufacture and supply both drugs for use in clinical trials and post commercialization on a cost plus basis. Atrium will be soley responsible for marketing the Products which incoporate the TAFA93 and ISA247 compounds. The license provided is for the use of TAFA93 and ISA247 in...See full deal structure in Biomedtracker
Partners: Atrium Medical Corporation
Additional information available to subscribers only: